Seventy patients with advanced cancer and refractory emesis were treated with subcutaneous boluses of levomepromazine (median daily dose: 6.25 mg; range: 3.12-25) in an open-label prospective study. Treatment was associated with a decrease in nausea from a median of 8/10 at baseline (IQR 7-8) to a median of 1 (IQR 0-2) after two days of treatment (P<0.0001); vomiting ceased in 92% of cases. It was possible to remove the nasogastric tube from all 11 patients who had one. The most frequently reported side effect was sedation, with a median of 2/10 (25-75% percentile 1-3), which was not correlated with the dose of levomepromazine. This study suggests that treatment with low-dose levomepromazine is an effective and safe option for advanced cancer patients who fail to respond to first-line antiemetic treatment.
Dunlop GM . A study of the relative frequency and importance of gastrointestinal symptoms, and weakness in patients with far advanced cancer . Palliat Med1989; 4: 37–43 .
2.
Faisinger R , Miller M , Bruera E , Hanson J , Macachern T . Symptom control during the last week of life on a palliative care unit . J Palliative Care1991; 7: 5–11 .
3.
Grond S , Zech D , Diefenbach C , Bischoff A . Prevalence and pattern of symptoms in patients with cancer pain: a prospective evaluation of 1635 cancer patients referred to a pain clinic . J Pain Symptom Manage1994; 9: 372–382 .
4.
Kai NG , von Gunten CF . Symptoms and attitudes of 100 consecutive patients admitted to an acute hospice/palliative care unit . J Pain Symptom Manage1998; 16: 307–315 .
5.
Mannix K . Palliation of nausea and vomiting. In Doyle D , Hanks G , MacDonald N eds. Oxford textbook of palliative medicine, second edition. Oxford: Oxford University Press , 1998: 489–499.
6.
Davis MP , Walsh D . Treatment of nausea and vomiting in advanced cancer . Support Care Cancer2000; 8: 444–452 .
7.
Twycross R , Back I . Nausea and vomiting in advanced cancer . Eur J Palliat Care1998; 5: 39–45 .
8.
Skinner J , Skinner A . Levomepromazine for nausea and vomiting in advanced cancer . Hosp Med1999; 60: 568–570 .
9.
Twycross R , Wilcock A . Symptom management in advanced cancer, third edition. Oxon: Radcliffe Medical Press , 2001: 104–111.
10.
Twycross R , Barkby G , Hallwood P . The use of low dose levomepromazine (methotrimeprazine) in the management of nausea and vomiting . Prog Palliat Med1997; 5: 49–52 .
11.
Oliver DJ . The use of methotrimeprazine in terminal care . Br J Clin Pract1985; 39: 339–340 .
12.
Higi M , Niederle N , Bierbaum W , Schmidt CG , Seeber S . Pronounced antiemetic activity of the antipsychotic drug of levomepromazine (methotrimeprazine) in patients receiving cancer chemotherapy . J Cancer Res Clin Oncol1980; 97: 81–86 .
13.
Lal S , Nair NP , Cecyre D , Quirion R . Levomepromazine receptor binding profile in human brain implications for treatment-resistant schizophrenia . Acta Psychiatr Scand1993; 87: 380–383 .
14.
Dahl SG , Strandjord RE , Sigfusson S . Pharmacokinetics and relative bioavailability of levomepromazine after repeated administration of tablets and syrup . Eur J Clin Pharmacol1977; 11: 305–310 .
15.
Eisenchlas J , Garrigue N , Junin M , De Simone G . J Pain Symptom Manage2000; 20: S63–S63 .
16.
Ellershaw JE , Murphy D , Shea T , Foster A , Overill S . Development of a multidisciplinary care pathway for the dying patient . J Eur Assoc Palliat Care1997; 4: 203–208 .
17.
Ananth JV , Lehmann HE , Ban TA . Agranulocytosis associated with methotrimeprazine (Nozinan) administration: a report of three cases . Can Med Assoc J1970; 102: 1286–1287 .
18.
Hatton MQ , McMurray A , Harnett AN . Ulcerative skin reaction from subcutaneous infusion of isotonic methotrimeprazine and diamorphine . Clin Oncol (R Coll Radiol)1995; 7: 268–269 .
19.
Hatta K , Takahashi T , Nakamura H , et al. A risk for obstruction of the airways in the parenteral use of levomepromazine with benzodiazepine . Pharmacopsychiatry1998; 31: 126–130 .
20.
Jarventausta K , Leinonen E . Neuroleptic malignant syndrome during olanzapine and levomepromazine treatment . Acta Psychiatr Scand2000; 102: 231–233 .
21.
Shimizu E , Watanabe H , Iyo M . Delayed-onset nocturnal akathisia due to risperidone and levomepromazine: a case report . Eur Psychiatry2002; 17: 294–295 .
22.
Gur H , Paz Y , Sidi Y . Acute dystonic reaction to methotrimeprazine hypoparathyroidism . Ann Pharmacother1996; 30: 957–959 .
23.
Dresner SM , Wayman J , Lovel T , Hayes N , Griffin SM . Percutaneous endoscopic duodenostomy: the relief of obstruction in advanced gastric carcinoma . Palliat Med1999; 13: 165–167 .
24.
Cannizzaro R , Bortoluzzi F , Valentini M , et al. Percutaneous endoscopic gastrostomy as a decompressive technique in bowel obstruction due to abdominal carcinomatosis . Endoscopy1995; 27: 317–320 .
Lichter I . Results of antiemetic management in terminal illness . J Palliat Care1993; 9: 19–21 .
27.
Del Favero A , Tonato M , Roila F . Issues in the measurement of nausea . Br J Cancer Suppl1992; 19: S69–S71 .
28.
Lang IM , Sarna SK . The role of adrenergic receptors in the initiation of vomiting and its gastrointestinal motor correlates . J Pharmacol Exp Ther1992; 263: 395–403 .
29.
Illhardt FJ , ten Have H . Research ethics in palliative care. In ten Have H , Clark D eds. The ethics of palliative care. Buckingham: Open University Press , 2002: 198–211.
30.
Bruera E , Belzile M , Neumann C , Harsanyi Z , Babul N , Darke A . A double-blind, crossover study of controlled-release metoclopramide and placebo for the chronic nausea and dyspepsia of advanced cancer . J Pain Symptom Manage2000; 19: 427–435 .
31.
Jackson WC , Tavernier L . Olanzapine for intractable nausea in palliative care patients . J Palliat Med2003; 6: 251–255 .
32.
Passik SD , Lundberg J , Kirsh KL , et al. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain . J Pain Symptom Manage2002; 23: 526–532 .
